Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Frailty and Healthy Ageing, Adelaide, SA, Australia.
Drugs Aging. 2023 May;40(5):449-459. doi: 10.1007/s40266-023-01025-5. Epub 2023 May 6.
Ensuring safe and effective analgesic use in residential aged care services is important because older adults are susceptible to analgesic-related adverse drug events (ADEs).
The aim of this study was to identify the proportion and characteristics of residents of aged care services who may benefit from analgesic review based on indicators in the 2021 Society for Post-Acute and Long-Term Care Medicine (AMDA) Pain Management Guideline.
Cross-sectional analyses of baseline data from the Frailty in Residential Sector over Time (FIRST) study (N = 550 residents) across 12 South Australian residential aged care services in 2019 were conducted. Indicators included the proportion of residents who received > 3000 mg/day of acetaminophen (paracetamol), regular opioids without a documented clinical rationale, opioid doses > 60 mg morphine equivalents (MME)/day, more than one long-acting opioid concurrently, and a pro re nata (PRN) opioid on more than two occasions in the previous 7 days. Logistic regression was performed to investigate factors associated with residents who may benefit from analgesic review.
Of 381 (69.3%) residents charted regular acetaminophen, 176 (46.2%) were charted > 3000 mg/day. Of 165 (30%) residents charted regular opioids, only 2 (1.2%) had no prespecified potentially painful conditions in their medical record and 31 (18.8%) received > 60 MME/day. Of 153 (27.8%) residents charted long-acting opioids, 8 (5.2%) received more than one long-acting opioid concurrently. Of 212 (38.5%) residents charted PRN opioids, 10 (4.7%) received more than two administrations in the previous 7 days. Overall, 196 (35.6%) of 550 residents were identified as potentially benefiting from analgesic review. Females (odds ratio [OR] 1.87, 95% confidence interval [CI] 1.20-2.91) and residents with prior fracture (OR 1.62, 95% CI 1.12-2.33) were more likely to be identified. Observed pain (OR 0.50, 95% CI 0.29-0.88) was associated with a lower likelihood of being identified compared with residents with no observed pain. Overall, 43 (7.8%) residents were identified based on opioid-related indicators.
Up to one in three residents may benefit from a review of their analgesic regimen, including 1 in 13 who may benefit from a specific review of their opioid regimen. Analgesic indicators represent a new approach to target analgesic stewardship interventions.
确保在养老院服务中安全有效地使用镇痛药非常重要,因为老年人容易发生与镇痛药相关的不良药物事件(ADE)。
本研究的目的是根据 2021 年社会康复和长期护理医学(AMDA)疼痛管理指南中的指标,确定可能需要进行镇痛药物审查的养老院服务居民的比例和特征。
对 2019 年在南澳大利亚州 12 家养老院服务中进行的随时间变化的居住在养老院的人群衰弱研究(FIRST)的基线数据(N=550 名居民)进行横断面分析。纳入的指标包括:每天接受>3000 毫克对乙酰氨基酚(扑热息痛)的居民比例、无明确临床理由使用常规阿片类药物、每日阿片类药物剂量>60 毫克等效吗啡量(MME)、同时使用超过一种长效阿片类药物、以及在过去 7 天内 PRN 阿片类药物使用超过两次的患者比例。采用 logistic 回归分析与可能需要进行镇痛药物审查的居民相关的因素。
在 381 名(69.3%)接受常规扑热息痛治疗的居民中,有 176 名(46.2%)接受了>3000 毫克/天的治疗。在 165 名(30%)接受常规阿片类药物治疗的居民中,仅有 2 名(1.2%)在病历中没有明确的潜在疼痛状况,31 名(18.8%)接受了>60 MME/天的治疗。在 153 名(27.8%)接受长效阿片类药物治疗的居民中,有 8 名(5.2%)同时使用了超过一种长效阿片类药物。在 212 名(38.5%)接受 PRN 阿片类药物治疗的居民中,有 10 名(4.7%)在过去 7 天内接受了两次以上的给药。总体而言,550 名居民中有 196 名(35.6%)被认为可能从镇痛药物审查中受益。女性(比值比[OR] 1.87,95%置信区间[CI] 1.20-2.91)和有既往骨折史的居民(OR 1.62,95% CI 1.12-2.33)更有可能被识别。与无观察到疼痛的居民相比,观察到疼痛(OR 0.50,95% CI 0.29-0.88)与较低的识别可能性相关。总体而言,有 43 名(7.8%)居民基于阿片类药物相关指标被识别。
多达三分之一的居民可能需要对其镇痛方案进行审查,其中 13 分之一的居民可能需要对其阿片类药物方案进行特定审查。镇痛指标代表了一种新的方法来确定镇痛药物管理干预措施的目标。